Celldex Therapeutics (CLDX) Set to Announce Earnings on Tuesday
Celldex Therapeutics (NASDAQ:CLDX) is scheduled to announce its Q313 earnings results on Tuesday, November 5th. Analysts expect the company to announce earnings of ($0.24) per share for the quarter.
Celldex Therapeutics (NASDAQ:CLDX) last announced its earnings results on Tuesday, August 6th. The company reported ($0.24) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.22) by $0.02. The company had revenue of $0.97 million for the quarter, compared to the consensus estimate of $1.57 million. During the same quarter last year, the company posted ($0.23) earnings per share. Celldex Therapeutics’s revenue was down 51.7% compared to the same quarter last year. On average, analysts expect Celldex Therapeutics to post $-0.97 EPS for the current fiscal year and $-1.02 EPS for the next fiscal year.
Celldex Therapeutics (NASDAQ:CLDX) traded up 4.24% during mid-day trading on Monday, hitting $23.58. 2,001,478 shares of the company’s stock traded hands. Celldex Therapeutics has a 52 week low of $5.02 and a 52 week high of $38.84. The stock has a 50-day moving average of $28.42 and a 200-day moving average of $20.09. The company’s market cap is $1.910 billion.
Several analysts have recently commented on the stock. Analysts at Oppenheimer reiterated a “buy” rating on shares of Celldex Therapeutics in a research note to investors on Tuesday, October 22nd. They now have a $40.00 price target on the stock. On the ratings front, analysts at Cantor Fitzgerald reiterated a “buy” rating on shares of Celldex Therapeutics in a research note to investors on Tuesday, October 22nd. They now have a $39.00 price target on the stock. Finally, analysts at Roth Capital raised their price target on shares of Celldex Therapeutics from $34.00 to $40.00 in a research note to investors on Tuesday, October 22nd. They now have a “buy” rating on the stock. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $35.13.
Celldex Therapeutics, Inc (NASDAQ:CLDX), is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.